Engitix Therapeutics
Andy Roland-Price is a finance leader with extensive experience in various roles across multiple organizations. Currently serving as Finance Director at Engitix Therapeutics since April 2024, Andy represents finance and legal functions on the Leadership Team. Prior to this, Andy held key positions at Purespring Therapeutics, where critical financial structures were established and significant funding was secured, and Forcefield Therapeutics, providing fractional finance support. A notable tenure at Imperial College London included securing £550 million in debt facilities, enhancing the endowment fund, and building a high-performing finance team. Earlier career experience encompasses roles at Star Energy, Centrica, the UK National Audit Office, and Procter & Gamble, where contributions led to manufacturing cost savings and advanced financial reporting methodologies. Andy holds an MEng in Biochemical Engineering from UCL and is a Fellow of the Institute of Chartered Accountants in England and Wales.
Engitix Therapeutics
To create a healthier future for patients with life-threatening diseases, Engitix Therapeutics is using its pioneering human extracellular matrix (ECM)-based discovery platform to develop a portfolio of programmes in fibrosis and solid tumors.